Date Filed | Type | Description |
10/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
10/10/2023 |
SC 13G/A
| FIL Ltd reports a 9.2% stake in BIOXCEL THERAPEUTICS INC |
10/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
10/04/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
09/28/2023 |
SC 13D
| BioXcel LLC reports a 32.5% stake in BioXcel Therapeutics, Inc. |
08/22/2023 |
8-K
| Other Events Interactive Data |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
06/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/29/2023 |
8-K
| Other Events Interactive Data |
06/28/2023 |
4
| Bray June (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Granted 17,000 options to buy
@ $17.52, valued at
$297.8k
|
|
06/28/2023 |
4
| MUELLER PETER (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Granted 17,000 options to buy
@ $17.52, valued at
$297.8k
|
|
06/28/2023 |
4
| MILLER MICHAEL PATRICK (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Granted 17,000 options to buy
@ $17.52, valued at
$297.8k
|
|
06/28/2023 |
4
| Laumas Sandeep (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Granted 17,000 options to buy
@ $17.52, valued at
$297.8k
|
|
06/28/2023 |
4
| Votruba Michal (Director) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Granted 17,000 options to buy
@ $17.52, valued at
$297.8k
Disposed of 17,000 options to buy
@ $17.52, valued at
$297.8k
|
|
06/16/2023 |
4
| Rodriguez Javier (See Remarks) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
06/16/2023 |
4
| Yocca Frank (Chief Scientific Officer) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
06/16/2023 |
4
| Steinhart Richard I (CFO) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
06/16/2023 |
4
| Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Sold 21,988 shares
@ $21.41, valued at
$470.8k
Sold 8,012 shares
@ $21.9, valued at
$175.5k
Sold 24,987 shares
@ $20.01, valued at
$500k
Sold 4,266 shares
@ $20.9, valued at
$89.2k
Sold 747 shares
@ $21.89, valued at
$16.4k
Exercised 2,609 restricted stock units
@ $0 Exercised 30,000 options to buy
@ $0.41, valued at
$12.3k
Exercised 30,000 options to buy
@ $0.41, valued at
$12.3k
|
|
06/16/2023 |
4
| O'Neill Vincent (Chief Medical Officer) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Exercised 521 restricted stock units
@ $0 |
|
05/24/2023 |
4
| Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Sold 6,500 shares
@ $25.7909, valued at
$167.6k
|
|
05/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/16/2023 |
4
| Mehta Vimal (CEO and President) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Exercised 15,000 restricted stock units
@ $0 |
|
05/16/2023 |
4
| Steinhart Richard I (CFO) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Sold 5,000 shares
@ $27.1727, valued at
$135.9k
Exercised 5,000 restricted stock units
@ $0 |
|
05/16/2023 |
4
| Rodriguez Javier (See Remarks) has filed a Form 4 on BioXcel Therapeutics, Inc.
Txns:
| Sold 1,785 shares
@ $27.3192, valued at
$48.8k
Exercised 5,000 restricted stock units
@ $0 |
|
05/16/2023 |
144/A
| Form 144/A - Report of proposed sale of securities: [Amend] |
05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/08/2023 |
8-K
| Quarterly results |
05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
04/20/2023 |
8-K
| Quarterly results |
04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|